Effective research depends on finding the most relevant model for the application. Our expert staff work with clients from concept to model creation using the latest CRISPR/Cas9* and RNAi technology to deliver the research animals they require for their studies. How can we help you? Request a quote or email us.
Learn more about this innovative technology by watching our webinar series.
To CRISPR or Not to CRISPR? IP, Technical Issues, & the 3Rs
In this webinar, we review the latest considerations for CRISPR technology used in genome editing for the creation of unique rodent models of human disease.
CRISPR/Cas9* Genome Editing: Model Creation, Gene Therapy, and Beyond
While the power CRISPR/Cas9* has to achieve targeted mutations in nearly any species is clear, what conclusions can we truly draw about its use in genome editing? This webinar answers this question and more.
CRISPR/Cas9*: The Good, The Bad, and The Ugly
This webinar presents how we've achieved deletions, duplications, and inversions of genomic regions as large as 24.4 Mb in rodents (the good). However, the limitations of modifying “big” genomic sequences (the bad) and how precise validation of the lines generated by CRISPR/Cas9* is demanded (the ugly) must be considered.
Modelling Human Disease in Rodents with CRISPR/Cas9* Genome Editing
Learn about the promise CRISPR/Cas9* has for rodent studies along with strategies for developing accurate and predictive models to better understand and treat human disease.
RNAi and CRISPR/Cas9*: Revolutionizing Drug Discovery
Learn how Charles River’s model creation partner, Mirimus, has leveraged RNA interference (RNAi) and CRISPR/Cas9* technologies to enhance the speed and precision of new genetically engineered mouse models.
The Cre-Toolbox: Revealing Gene Functions with Cre-lox Recombination
After a brief introduction of the Cre-lox technology, this webinar discusses using Cre-lox to understand pleiotropy and dissecting gene functions, overcoming embryonic and early postnatal lethality Inducible inactivation with the creERT2 system, phenotypes induced by Cre driver, Tamoxifen toxicity, and Cre leakiness.
* CRISPR/CAS9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.